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Background: Overexpression or mutation of the epidermal growth factor receptor (EGFR) potently enhances the
growth of many solid tumors. Tumor cells frequently display resistance to mechanistically-distinct EGFR-directed
therapeutic agents, making it valuable to develop therapeutics that work by additional mechanisms. Current
EGFR-targeting therapeutics include antibodies targeting the extracellular domains, and small molecules inhibiting
the intracellular kinase domain. Recent studies have identified a novel prone extracellular tetrameric EGFR configuration,
which we identify as a potential target for drug discovery.
Methods: Our focus is on the prone EGFR tetramer, which contains a novel protein-protein interface involving
extracellular domain III. This EGFR tetramer is computationally targeted for stabilization by small molecule ligand
binding. This study performed virtual screening of a Life Chemicals, Inc. small molecule library of 345,232 drug-like
compounds against a molecular dynamics simulation of protein-protein interfaces distinct to the novel tetramer. One
hundred nine chemically diverse candidate molecules were selected and evaluated using a cell-based high-content
imaging screen that directly assessed induced internalization of the EGFR effector protein Grb2. Positive hits were
further evaluated for influence on phosphorylation of EGFR and its effector ERK1/2.
Results: Fourteen hit compounds affected internalization of Grb2, an adaptor responsive to EGFR activation. Most hits
had limited effect on cell viability, and minimally influenced EGFR and ERK1/2 phosphorylation. Docked hit compound
poses generally include Arg270 or neighboring residues, which are also involved in binding the effective therapeutic
cetuximab, guiding further chemical optimization.
Conclusions: These data suggest that the EGFR tetrameric configuration offers a novel cancer drug target.
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For many solid tumors, overexpression or activating mu-
tation of the epidermal growth factor receptor (EGFR)
serves as an oncogenic driver. Even in some tumors in
which EGFR is not overexpressed, it can serve as an essen-
tial intermediate in signaling required for cell growth and
survival [1, 2], reflecting its role as a potent regulator of
multiple downstream effector cascades, including PI3K/
AKT/mTOR, JAK/STAT, and RAS/RAF/MEK. Because of* Correspondence: Erica.Golemis@fccc.edu; Eileen.Jaffe@fccc.edu
1Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman
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© 2015 Ramirez et al.this prominent role, multiple therapeutic agents targeting
EGFR have been developed. These include monoclonal
antibodies such as cetuximab and panitumumab, which
target the extracellular domain, and small molecule inhibi-
tors including erlotinib, gefitinib, lapatinib, and afatinib,
which target the cytosolic kinase domain. These agents
often provide significant clinical benefit, but are some-
times ineffective because of intrinsic or acquired tumor
resistance factors. Mechanisms of resistance can include
expression of an EGFRvIII variant [3], which eliminates
the epitope for some monoclonal antibodies, or missense
mutations involving the EGFR kinase domain (e.g.,
T790M), among others [4]. The frequent occurrence of
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some cancers has motivated ongoing efforts to identify
additional agents that use independent mechanisms to in-
hibit EGFR [5]. Further, the combination of multiple clas-
ses of inhibitory agents has been recently recognized to
provide thorough blockade of EGFR signaling and can
yield significant clinical benefit [6, 7]; this provides a
strong motivation to enlarge the suite of mechanistic op-
tions for EGFR inhibition.
EGFR protein structure and protein interactions have
been the subject of intensive study [8, 9]. As a transmem-
brane, ligand-dependent receptor tyrosine kinase, EGFR
contains an extracellular N-terminal moiety comprised of
four discrete domains (Domains I-IV), a transmembrane
domain, an intracellular juxtamembrane domain, and a
C-terminal intracellular kinase domain. Unliganded EGFR
is predominantly monomeric, with very low propensity to
dimerize. EGFR monomers exist in an equilibrium of con-
formations, at least one of which is competent to dimerize
with a second EGFR monomer (estimated at ~5 % of the
monomer population). Binding of EGF or other ligands to
domains I and III stabilizes the protein conformer that is
competent for dimerization, thus increasing its mole frac-
tion within the monomer population and promoting
dimerization [10, 11]. The dimerization-competent con-
former contains domain II in an exposed, rather than bur-
ied environment. Dimeric EGFR binding to two molecules
of EGF is characterized by high-affinity and low-affinity
events, which are proposed to represent an initial high-
affinity binding event that favors an asymmetric dimeric
structure in which the second subunit is sterically pre-
vented from binding ligand [12]. In the dimeric conform-
ation, each EGF binding site is comprised of only one
EGFR subunit. Binding of dimeric EGFR to two molecules
of EGF favors a conformation of the kinase domain that
activates intracellular auto-phosphorylation and initiates
downstream signaling events. Subsequently, ligand-bound
EGFR is internalized from the cell surface, limiting the
duration of signaling [13].
In the physiologic context of the cell surface, this basic
and elegant paradigm acquires additional nuance. A num-
ber of studies have demonstrated that patches or “rafts”
on the cell surface, enriched in specific lipids such as
cholesterol, allow concentration of EGFR in clusters
that support accumulation of unliganded dimeric and
higher-order oligomeric species, including tetramers
[14–17]. These pre-formed dimers and multimers have
been associated with specific activity states of EGFR
(discussed in [18]). The oligomeric state of EGFR may
also be relevant to oncogenic transformation, given that
the overexpression of EGFR that is common in and
driver for many solid tumors (reviewed in [19]) would
be expected to promote oligomerization. While most
studies have addressed the protein packing events associatedwith tetrameric conformations defined as “back-to-back” or
“side-to-side”, in which EGFR protrudes at a 90° angle to
the cell membrane, an intriguing group of studies have
supported the existence of a physiological “head-to-head”
tetramer, in which the extracellular domains of EGFR lie
prone along the plasma membrane (Fig. 1a) [17, 20, 21].
The biological significance of an EGFR tetramer as a key
signaling unit is well documented [22, 23]. However, it is
possible that EGFR can form each of the proposed archi-
tecturally distinct tetrameric assemblies and that these
multimers have distinct functions. This is consistent with
the myriad functions that have been attributed to assem-
blies larger than a dimer. The four EGF binding sites in
the “head-to-head” prone tetramer have an intrinsic asym-
metry. Two of these sites are at the dimer-dimer interface;
EGF binding affinity is strengthened by interactions from
a second subunit, which has been proposed as an alterna-
tive explanation for the high affinity mode of EGF binding
to EGFR. If so, targeting the unique structural features of
the prone tetramer would be predicted to provide an
entirely new approach to disrupting early stages of the
EGFR activation process. The ability to form higher
order oligomeric complexes is not restricted to EGFR.
Landgraf and colleagues have elegantly demonstrated
that heteromeric complexes of the EGFR family members
Her2 and Her3 can form functional oligomers of heterodi-
mers and that this complex formation can be modulated
by a specific aptamer [24–27]. In the current study, we
have combined molecular docking targeted at the EGFR
tetramer interface with a high throughput microscopy
based screen to identify compounds that influence EGFR
internalization, either independently or contingent upon
the presence of EGF.
Methods
Virtual docking and in silico compound selection
Coordinates for a theoretical prone head-to-head tetramer
were obtained from the laboratory of Dr. Martyn Winn
and are included as Additional file 1: Data file S1 [20].
The coordinates indicating the corners of the three dock-
ing boxes 1, 2, and 3 are included as Additional file 2: Data
file S2; Additional file 3: Data file S3 and Additional file 4:
Data file S4, respectively. The tetramer coordinates in-
clude EGF bound to EGFR, and EGF was retained in the
coordinates for docking preparation and docking. The
protein preparation wizard from Maestro (Schrödinger
Suite 2010 Protein Preparation Wizard; Epik version 2.1,
Schrödinger, LLC, New York, NY, 2010; Impact version
5.6, Schrödinger, LLC, New York, NY, 2010; Prime version
2.2, Schrödinger, LLC, New York, NY, 2010) was used to
prepare the receptor model for docking and to define
docking boxes.
A flow chart depicting the docking process is included
as Additional file 5: Figure S1. Compounds from the in-
Fig. 1 Virtual screening methods identify candidate EGFR multimer stabilizers. Panel a depicts a simple cartoon showing unliganded EGFR
monomer in the context of the plasma membrane (PM), the EGF-bound EGFR upright dimer, and the EGF-bound prone tetramer. Panel b depicts
a structural model of two canonical back-to-back EGF-bound EGFR dimers (extracellular portion, each with one monomer in ribbons and the other
in spacefill) that further multimerize to form a tetramer along a novel head-to-head interface (dashed line). Each monomer is colored by domain:
I–cyan, II–orange, III–green, IV–pink, bound EGF–purple, with the chains of one canonical dimer in dark shades and the other in light shades. Dashed
ovals indicated the approximate positions of the three docking boxes (2, 3 and 1) that were explored to identify small molecule ligands proposed
to bind to and stabilize the novel interface. c A detailed view of Box 2 illustrates the boundaries in which docked molecules must be contained
(purple) and in which the center of the docked molecules must be located (green). Identified hits that docked in Box 2 are shown in ball-and-stick
representation with the carbons colored in yellow (F5230-0424) or cyan (F2738-2186) or white (F2573-0380) and other atoms in CPK. Boxes 3 and 1
are similarly detailed in panels d and e; hits are shown with the carbons in white or yellow (Box 3: F0922-0900 and F3385-3143 respectively, Box 1:
F3109-0096). The views in panels c-e have slightly different rotations to optimally show the orientation of the boxes and ligands. Molecular details
and interactions for each of the ligands are shown in Fig. 5
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drug-like small molecules, were prepared for in silico
docking using LigPrep version 2.5 and QikProp, version
3.3 (Schrödinger, LLC, New York, NY, 2010). An esti-
mate of solubility (LogS) was generated for each com-
pound using QikProp and compounds were filtered using
a cutoff of −6.0 for LogS. All tautomers and stereoisomers
as well as possible ionization states at pH 7.0 were gener-
ated for each compound in the filtered set. These com-
pounds were first docked using the Glide version 5.6
software package (Schrödinger, LLC, New York, NY, 2010
[28–30]) in Standard Precision mode, which emphasizes
goodness-of-fit of the drug-like small molecules to the de-
fined protein surface cavities. The best scoring 10 % ofcompounds were then re-prepared using LigPrep, and
again docked using Extra Precision mode, which empha-
sizes the energetics of the interaction between the small
molecule and the protein (e.g., charge, hydrophobicity).
The best scoring 10 % of compounds from the Extra Pre-
cision docking were combined for the three docking boxes
(~5000 compounds per box) and divided into two sets
based on whether or not the compound as docked was
within 4Å of either EGF molecule in the dimer interface
of the prone tetramer receptor model. Each set was fil-
tered to remove duplicates, as well as different tautomers
or stereoisomers of the same compound. The remaining
compounds in each set were then filtered to improve
chemical diversity. In the Life Chemicals libraries, the first
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larity. Families of compounds with the same first four digit
ID were further reduced to include only the highest scor-
ing member. This brought both the “contacts EGF” and
“does not contact EGF” sets to below 1000 molecules
each. All compounds were then viewed as docked on the
receptor and manual selection was based on docking pos-
ition to maximize diversity of docking locations on the
EGFR dimer. One hundred nine compounds were selected
for functional evaluation, with the selection biased to ap-
proximately 75 % of the chosen compounds as not pre-
dicted to interact with EGF.
Grb2 internalization assay and compound selection metrics
Time points for assessment of Grb2 were selected based
on studies of the recycling of the EGFR signaling complex
[31–33], as well as empirical optimization of signaling in
initial time course experiments. Drug concentrations for
test compounds and cetuximab and erlotinib reference
compounds were selected based on values in the literature
used for compound screening and/or analysis of EGFR-
related signaling [34, 35]. 6 × 103 SCC61 cells were plated
in each well of a poly-lysine (cat # P482, Sigma, St. Louis,
MO) coated 96-well plate 24 h prior to screening. Four
hours prior to compound addition, cells were starved in
DMEM/F12 and 0.2 % FBS. After starvation, compounds
at 5 mM dissolved in DMSO or DMSO vehicle were
added to cells by pin tool transfer on a CyBi-Well Vario
equipped with a 100 nl pin tool (V and P Scientific, San
Diego, CA) for a final concentration of 10 μM compound.
After 5 min, EGF (10 ng/ml in serum free media) or ve-
hicle was added. After 50 min, cells were washed once
with PBS, and fixed for ten minutes at room temperature
in 4 % PFA. Cells were washed 3 times with PBS, and
permeabilized in 0.2 % Triton. Cells were incubated with
primary Grb2 antibody (#3972, Cell Signaling, Danvers,
MA used at 1:500 in 0.2 % BSA) for 2 h at room
temperature. Cells were washed 3 times and subsequently
incubated with secondary antibody (#A11008 anti-rabbit
Alexa 488, Life Technologies, Carlsbad, CA) diluted in
0.2 % BSA for 2 h. Cells were washed as before and incu-
bated with DAPI prior to imaging. Controls used to evalu-
ate screen performance included wells treated with or
without EGF, with added vehicle control, cetuximab
(2 μM) or erlotinib (20 μM).
An average of twelve × 20 images per well were acquired
utilizing the Image Xpress micro high content imaging
system (Molecular Devices, Downingtown, PA) driven by
Meta Xpress software. Images were analyzed with the
Transfluor Meta Xpress image analysis module and results
were displayed and exported utilizing the Acuity Xpress
software package (Molecular Devices). Plates were ranked
for inclusion based on the ratio of raw pit count per well
for EGF versus untreated controls. Plates with ratios below1.5 were excluded from analysis. Two normalization
methods were used; the first method normalized each par-
ameter to the mean-of-the plate same parameter; the sec-
ond method normalized to mean of vehicle (per run)
same parameter. The normalized data was used to calcu-
late the ratio of +EGF to -EGF conditions. In the primary
screen, hit selection was based on the parameter sum of
pit count per well. Hits were ranked by FDR, and by the
EGF-to-vehicle ratio for the parameter total pit count.
Immunoblot assays and analysis
SCC61 cells were plated at the density of 6000 cells/
0.32 cm2 in 6-well plates. The next day cells were pre-
treated with Vehicle (DMSO), controls (erlotinib at
20 μM, cetuximab at 4 μM, or drugs at 10 μM at 37 °C
for 5 min, and then 10 ng/ml EGF (final concentration)
was added to each well. After 15 min or 40 min at 37 °C
as indicated, cell culture media was removed and cells
were immediately washed once with cold PBS. These
time points were taken to parallel the process of EGFR/
Grb2 recycling, and correspond to time periods known
to reflect maximal changes in activity following EGF
stimulation [31–33]. Cells were then lysed in Mammalian
Protein Extraction Reagent (MPER™, Thermo Scientific,
Waltham, MA) for about 20 min on ice. Lysis buffer was
supplemented with Halt™ Phosphatase and Protease In-
hibitor Cocktail (Thermo Scientific). After collection,
lysates were centrifuged at 17,000 × g at 4 °C for 15 min,
and protein concentrations were determined using the
BCA assay (Thermo Scientific, Waltham, MA). Samples
were boiled in Lane Marker Reducing Sample Buffer
(Thermo Scientific, Waltham, MA) for 5 min. Proteins
were resolved on 8 % SDS-PAGE gels and transferred to
PVDF membrane (EMD Millipore, Billerica, MA). Mem-
branes were blocked in Odyssey Blocking Buffer, incu-
bated overnight at 4 °C in primary antibody, followed by
IRDye®-conjugated secondary antibody and signal detected
with Odyssey Infrared Imaging System (all from LI-COR
Biosciences, Lincoln, NE). Vinculin was used as loading
control. Antibodies are used as follows: pMAPKT202/Y204
(#9101), MAPK (#4696), and EGFR (#4267) from Cell
Signaling, Danvers, MA); pEGFRY1173 (#44794G, from
Invitrogen, Carlsbad, CA); and vinculin (#A1978, from
Sigma-Aldrich, St. Louis, MO). Immunoblots were quanti-
fied using Image Studio Software (http://www.licor.com/
bio/products/software/). The ratio of phosphorylated to
total protein was calculated and normalized to the value
of the positive control for each experiment (vehicle only,
in the presence of EGF).
Viability determination and drug synergy
Viability in response to compound alone or compounds
in combination with erlotinib or cetuximab was deter-
mined with the CellTiterBlue assay (Promega, Madison,
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4000 cells/well) 24 h prior to addition of compounds,
transferred into 96 well plates as described above. For
these experiments, lower doses of cetuximab and erloti-
nib were used than for screening, to maximize the
chance of identifying synergy with newly identified com-
pounds. Cetuximab was added to 4 μM and erlotinib to
2 μM. Cells were incubated for 72 h after which 5 μl of
CTB reagent was added. Fluorescence intensity was
measured on an Envision Multilabel plate reader (Perkin
Elmer, Waltham, MA) at 2 h after CTB addition.
Results
In silico selection of compounds targeting a prone EGFR
tetramer
The structure of a membrane-aligned EGFR tetramer
with bound EGF ligand (Fig. 1b) was generated using
molecular dynamics simulation to yield the head-to-
head prone tetramer (coordinates provided by Martyn
Winn; see Additional file 1: Data S1) [20]. In contrast to
the back-to-back, membrane-protruding EGFR dimer,
the head-to-head configuration is uniquely predicted to
contain a tetramer-specific interface between the 2 di-
mers that could potentially bind small molecules. Ligand
binding along this interface is predicted to stabilize the
tetramer, increase its mole fraction, and promote its
function. To support virtual screening for small mol-
ecule agents that would specifically bind the tetramer,
the interface was divided into three overlapping docking
boxes (coordinates provided in Additional files 2, 3 and
4: Data S2–S4, illustrated in Fig. 1c, d and e, and quanti-
fication of the docking process is provided as a flow
chart Additional file 5: Figure S1; computational limita-
tions prevented our simultaneous docking along the
entire interface. One box included the EGF ligands and
two boxes flanked the EGF binding site, but did not
include EGF.
The Life Chemicals, Inc. library of 345,232 small mole-
cules was prescreened for drug-like properties; the result-
ant set of compounds was then re-expanded to consider
all potential tautomeric isoforms, giving 496,398 candidate
ligands. Using Glide software (see Methods), the candidate
ligands were docked to each of the three boxes (~1.5
million docking processes). The top scoring 15,000 com-
pounds were manually filtered to select compounds with
chemically diverse scaffolds interacting with the greatest
variety of discrete elements within the docking boxes.
Based on this analysis, 109 candidate ligands were selected
for purchase and in vitro analysis. All purchased com-
pounds docked within 4Å of both EGFR molecules; 27
also docked within 4Å of at least one EGF molecule
(Additional file 6: Table S1). None of the compounds
are chemically similar to known small molecule inhibi-
tors of the EGFR kinase domain, such as erlotinib.Candidate compounds alter internalization of the EGFR
effector Grb2
Following activation by EGF-induced dimerization and
autophosphorylation, EGFR recruits a group of binding
partners including the scaffolding protein Grb2 to trans-
mit proliferative and other signals. EGFR activity is sub-
sequently limited by the internalization of EGFR, Grb2,
and associated signaling proteins through coated pits to
early endosomes, followed by recycling to the membrane
or trafficking to lysosomes for destruction (Fig. 2a). This
process of internalization followed by recycling or de-
struction takes between 30 and 90 min, and is influenced
by a number of feedback loops [31–33]. Clinically rele-
vant inhibitors of EGFR influence its internalization,
inhibit its autophosphorylation, or both [36–38]. For
antibodies targeting the extracellular domain of EGFR
and altering its oligomerization state, changes in in-
ternalization properties are readily apparent in cell cul-
ture. We posited that targeted small-molecule stabilization
of the EGFR tetramer would also affect internalization
and recycling.
We developed a high-content fluorescence microscopy-
based screen to assess candidate compound activity in in-
fluencing internalization of the EGFR effector Grb2 in
SCC61 cells, a head and neck squamous cell carcinoma
cell line that expresses abundant EGFR [39]. We chose
to use Grb2 as a surrogate marker because it was unclear
how EGFR activity state, reflected by auto-phosphorylation,
would be affected by addition of compounds, while EGFR
dimerization was typically associated with internalization of
its signaling partners. Grb2 localization was determined
utilizing an imaging approach with acquisition of 12
images/well and scoring for Grb2 positive pit formation.
Comparison of untreated and EGF-treated cells illustrates a
robust dynamic range (Fig. 2b). For screening, SCC61 cells
were pre-treated with compounds for 5 min, and then
treated with EGF (10 ng/ml) or vehicle for 50 min. Com-
pounds that alter Grb2 positive pit formation could fall into
one of 4 possible classes. Class 1-reduces pits in the pres-
ence of EGF; Class 2-increases pits in the presence of EGF;
Class 3-reduces pits in the absence of EGF and Class
4-increases pits in the absence of EGF. Pit count phe-
notypes were grouped based on the normalized ratio
of pit count with and without EGF and identified as
belonging to one of the four Classes. Fourteen prelim-
inary hit compounds were selected for further analysis,
based on phenotypic robustness as well as the com-
bination of phenotype and whether or not the docked
location predicted interaction with EGF.
As anticipated, Grb2-positive pits induced by EGF
treatment were reduced by the control EGFR inhibitors
cetuximab and erlotinib (Fig. 2c). Among compounds
screened, F0922-0900 represents a Class 1 hit compound,
F2738-2186 represents a Class 2 hit compound, and
Fig. 2 (See legend on next page.)
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Fig. 2 Evaluation of compounds for their effect on internalization of Grb2. a Schematic of EGFR internalization cycle through Grb2-positive early
endosomes (EE) and late endosomes (LE) [23]. b SCC61 cells treated with vehicle or EGF, visualized with antibody to Grb2. Right panels represent
image overlayed with object mask generated by the Transfluor module. c Representative fields for untreated versus EGF-treated cells pre-incubated
with controls (vehicle, erlotinib, cetuximab) or indicated compounds. d Quantitation of changes in pit count ratio; numbers over the bars indicate the
docking boxes for each compound; + indicates that docking pose predicts EGF interaction. Class 1 and 2 compounds are reported comparing
EGF-to-vehicle ratio in the absence of compounds versus EGF-to-vehicle ratio in the presence of compound, representative screening data.
Compound classes are indicated. Representative screening data for Class 4 compounds are reported comparing pit count ratio for compound
alone normalized to vehicle indicating activity in the absence of EGF
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compounds were identified in Class 3. Typical screen
results for the 14 preliminary hit compounds are
shown in Fig. 2d, with results normalized to EGF-
treated cells, or with results normalized to untreated
baseline conditions to emphasize Class 4. The most
effective Class I and Class 4 hit compounds had con-
tact sites that were dispersed across the entire dimer-
dimer interface, while the two robust Class 2 hit
compounds were derived from a flanking box that
largely avoids EGF.Fig. 3 Viability of SCC61 and A431 cells treated with test compounds. a SC
indicated agents. Erlotinib (grey bars) was used at 2 μM, and cetuximab (white
reference to vehicle treated cellsCompound effect on cell viability
The 14 preliminary hit compounds were independently
assessed for their influence on cell viability, with effects
benchmarked to the EGFR-inhibiting agents erlotinib
and cetuximab. We also assessed whether these com-
pounds could potentiate the effects of erlotinib or cetux-
imab on cell viability. For these analyses, we employed
both the EGFR-expressing SCC61 cells, which were used
for initial candidate compound screening (Fig. 3a), and a
second highly EGFR-dependent cell line, A431 human
squamous carcinoma cells (Fig. 3b).C61 or b A431 cells were treated for 72 h with vehicle (black bars) or
bars) at 4 μM, while test compounds were used at 10 μM. *, P <0.05 in
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cetuximab significantly affected cell viability after 72 h
of incubation. Under these conditions, 10 μM of the
Class 2 compound F2738-2186 reduced cell viability by
25 % relevant to vehicle treated cells (p = 0.0064)
(Fig. 3a). Combination of F2738-2186 with erlotinib or
cetuximab did not further decrease viability in refer-
ence to F2738-2186 used alone. Class 4 compound
F5230-0424 modestly reduced viability in combination
with erlotinib (p value 0.001).
In contrast, the same concentrations of erlotinib (p =
0.0001) and cetuximab (p = 0.0001) both significantly
reduced cell viability in A431 cells. Interestingly, no
test compound significantly reduced the viability of
A431 cells, although one Class I compound, F3385-
3143, significantly increased cell viability (p = 0.0171)
(Fig. 3b). However, in combination with erlotinib,
two Class 4 compounds modestly but significantly en-
hanced the erlotinib-dependent decrease in cell viabil-
ity. Further, in combination with cetuximab, a number
of compounds showed a trend towards decreased
viability, although results did not rise to statistical
significance.EGFR-Y1068, EGFR-Y1173, and ERK1/2-T202/Y204 phosphorylation
in response to compound treatment
To assess whether the preliminary hit compounds influ-
enced the activity state of EGFR or its downstream
effector ERK1/2, SCC61 cells were treated with vehicle,
cetuximab, erlotinib, or 1 of 6 of the preliminary hits for
1 h, and then treated with EGF or vehicle for 45 min.
Whole cell lysates were then analyzed for levels of total,
Y1068-phosphorylated, and Y1173-phosphorylated EGFR,
and total or T202/Y204-phosphorylated ERK1/2 (Fig. 4a, b
and c). In vehicle-treated cells, in the absence of EGF,
very low basal phosphorylation of EGFR and ERK1/2
was observed, while EGF treatment induced EGFR-
Y1068-phosphorylation 5.4-fold, EGFR-Y1173-phosphoryl-
ation 8.2-fold, and ERK1/2-T202/Y204 phosphorylation
3.6-fold.
Each of these EGF-induced phosphorylation events
was entirely blocked by treatment with the EGFR kinase
inhibitor erlotinib. In contrast, cetuximab treatment
slightly elevated EGF-induced Y1173-EGFR phosphoryl-
ation. Among the compounds assessed, the two Class 2
compounds, F2738-2186 and F2573-0380, each also
slightly elevated EGF-dependent Y1173-EGFR phosphor-
ylation, while the class I compound F0922-0900 slightly
reduced this phosphorylation. Neither cetuximab nor
any of the six preliminary hit compounds tested signifi-
cantly affected Y1068-EGFR phosphorylation. Finally,
F2573-0380 slightly increased basal levels of T202/Y204-
ERK1/2, in the absence of EGF treatment.Analysis of hit compounds
The data obtained from screening and biological assays
are summarized in Additional file 7: Table S2. Among
the 14 compound hit set, 4 of the 14 were derived from
the subset (28 %) of the total library that is predicted to
interact with EGF. Of the six compounds evaluated for
their effects on phosphorylation (Fig. 5), 2 of the 6
(33 %) are predicted to interact with EGF. The predicted
binding pockets have some distinct commonalities. With
regard to molecular interactions, Fig. 5 shows that 4 of
the 6 hits dock to Arg-470, and the 2 that are not pre-
dicted to interact with this residue, are predicted to inter-
act with neighboring residues (e.g., Ser-468, Asn-469, Glu-
472, Asn-473). For the compounds that are predicted to
interact with EGF, the putative EGF interactions all in-
volve EGF residues in the region of Lys48-Leu52.
Discussion
Based on the data presented above, 14 of 109 compounds
predicted to stabilize a recently defined homo-tetramer of
EGFR influenced intracellular trafficking of the EGFR ef-
fector Grb2. As with the EGFR-binding antibody cetuxi-
mab, these compounds had little effect on EGFR auto-
phosphorylation, or activation of the EGFR effector ERK1/
2. Encouragingly, several compounds potentiated the
activity of clinical EGFR inhibitors. While the identified
compounds are implied to bind to tetrameric EGFR,
where domain III is a component of the tetramer inter-
face, cetuximab binds to domain III of monomeric
EGFR in a conformation that is not competent for multi-
merization (PDB id 1YY9 [40]). Thus both are targeted to
modulate the EGFR quaternary structure equilibrium, but
with different stabilization targets, allowing a combination
therapy to target multiple EGFR structural isoforms to
limit the quaternary structure dynamics essential for
EGFR function. These findings in sum suggest that tar-
geting the extracellular EGFR prone tetramer is a strat-
egy worthy of further evaluation in identification of
clinical leads.
Homo-multimer stabilization as an approach to allo-
steric drug discovery is gaining momentum as more
drug targets are appreciated to participate in quaternary
structure equilibria among functionally distinct homo-
meric assemblies [41–43]. In prior work, we have used a
carefully constructed homology model of a homo-
multimeric enzyme as a target for the identification
of multimer-specific allosteric inhibitor molecules [44]. In
that case the quaternary structure equilibrium includes
high activity octamers and low activity hexamers whose
interconversion requires dissociation, hinge motion, and
re-association events [45]. Using the unique prone tetra-
mer of EGFR as a target, we deduced that stabilization of
the head-to-head interface could potentially alter EGFR
function by shifting the equilibrium toward this tetramer.
Fig. 4 (See legend on next page.)
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Fig. 4 EGFR and ERK1/2 phosphorylation following treatment of SCC61 cells with test compounds. a Averaged quantification of Western blots
analyzing Y1068- or Y1173-phosphorylated EGFR following 1 h pre-treatment with compounds, vehicle, cetuximab, or erlotinib, followed by 45 min
treatment with vehicle or EGF +/− EGF. Values shown are normalized to total EGFR. b Averaged quantification of Western blots analyzing T202/
Y204-phosphorylated ERK1/2 following 1 h pre-treatment with compounds, vehicle, cetuximab, or erlotinib, followed by 45 min treatment with
vehicle or EGF +/− EGF. Values shown are normalized to total ERK1/2. c Representative Western blots for quantified data shown in parts a and b
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this study of regulation of Grb2 internalization is similar
to our prior studies that used in silico docking followed by
in vitro validation to identify multimer-specific allosteric
inhibitors [44, 46], and is presumed to be far above that
expected for 100 randomly selected drug-like compounds,
providing support to the tetramer model.Fig. 5 Identified hits in their docked poses highlighting key intermolecular
interactions. Panels a-c show ligands that dock in Box 2, panels d and e
show ligands that dock in Box 3, panel f shows ligands that dock in Box 1.
Each ligand is shown in ball-and-stick representation with the carbons in
black and other atoms in CPK. The surrounding binding pockets formed
by EGFR and EGF are shown as transparent surfaces and are colored by
domain as in Fig. 1. In each panel, residues from EGFR or EGF that form
hydrogen bonds or ring-stacking hydrophobic interactions with the ligand
are shown as spheres with the carbons colored by domain and other
atoms in CPK. Hydrogen bonds are shown as dashed red lines. The
orientation varies among the panels to best show the structure of
each ligandOur use of Grb2 internalization as a readout for
stabilization of the EGFR tetramer was recently validated
by an elegant biophysical analysis of EGFR multimeriza-
tion and its relationship to Grb2 association [23]. That
study, which employed fluorescence energy transfer
methods, a C-terminal GFP-labeled EGFR, and an RFP-
labeled Grb2, concluded that, for these labeled con-
structs, 2 % of EGFR is monomeric, 5 % is dimeric, <1 %
is trimeric, and 94 % is tetrameric. Cluster distribution
at 10 nM EGF shows nearly 95 % of the EGFR tetramers
containing at least one bound Grb2, while monomers,
dimers, and trimers are predominantly (~98 %) free of
Grb2. However, identification of compounds in the Grb2
screening assay is not diagnostic of the mechanism of
action of the compound; it is formally possible that the
compounds are stabilizing, destabilizing, or not affecting
stability, but rather altering EGFR oligomeric structure
in a manner that impacts the magnitude or the kinetics
of internalization and recycling. These points all bear
further investigation. It will be important to perform clas-
sic medicinal chemical optimization, and establishment of
structure-activity relationships in relation to the docking
boxes to validate the mode of action of compounds emer-
ging as hits. Finally, further investigation of the com-
pounds identified in this screen should expand to explore
their effect on the mobilization of total and phosphory-
lated (active) EGFR, and other EGFR-dependent effector
pathways.
Conclusion
Our current study demonstrates that focusing on EGFR
tetramer-specific surface cavities as targets for virtual
screening, combined with a high content cell-based
screening approach, can identify novel compounds that
modulate EGFR function, presumably via a novel mech-
anism. While the current studies do not establish
whether the active compounds bind to the EGFR tetra-
mer as predicted by docking, nevertheless, the cited
demonstration that Grb2 specifically interacts with a
tetrameric form of EGFR provides an exciting validation
to hypotheses that drove our experimental design.
Additional files
Additional file 1: Coordinates for the prone EGFR tetramer.
Additional file 2: Coordinates for docking box 1.
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Additional file 4: Coordinates for docking box 3.
Additional file 5: Figure S1. Flow Chart describing computational
docking of the Life Chemicals, Inc. small molecule library to the head-to-
head prone model of tetrameric EGFR.
Additional file 6: Table S1. Life Chemicals, Inc. compounds selected
for in vitro characterization. Presented are the chemical structures,
manufacturer’s ID, molecular weight, and the Glide XP score.
Additional file 7: Table S2. Summary table of compounds selected
from primary screen and activity in secondary assays. Life Chemicals, Inc.
compounds selected for in vitro characterization. Presented are the,
manufacturer’s ID, chemical structures, hit class determined in the
primary screen (see Fig. 2), activity in EGFR pY1173 western analysis
(see Fig. 4), activity in phospho-ERK western analysis (see Fig. 4), activity
in viability assays of SCC61 cells, and activity in viability assays of A431
cells. S.S. denotes statistically significant, N.S. denotes not significant,
and - - denotes not determined.
Abbreviations



























The authors declare that they have no competing interests.
Authors’ contributions
UDR performed the computational docking studies through selection of the
compounds for in vitro characterization. ASN and HL performed Western
analysis of signaling consequences of compound administration. AP
performed the screen and image acquisition and image analysis. SHL
designed and executed the preparation of the molecular illustrations. IGS
provided extensive input on data analysis for the in vitro studies. YZ
supervised the image-based data and statistical analysis. MKR assisted in
designing the cell-based Grb2 internalization screen. MBE designed the
cell-based Grb2 internalization screen and supervised its execution. EAG and
EKJ collaboratively developed the overall rationale for the described studies
and wrote the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
The authors were supported by pilot funding from the Fox Chase Cancer
Center Head and Neck Keystone Program; NIH R01 ES003654-27 (to EKJ); R21
CA181287 and R01 CA063366 (to EAG); by a subsidy of the Russian Government
to support the Program of competitive growth of Kazan Federal University (to
IS); and by the NIH Cancer Center Core Grant P30 CA006927 (to Fox ChaseCancer Center). We acknowledge Cynthia Myers of the FCCC Organic
Synthesis Facility for confirming the molecular structures of the hit
compounds. We graciously thank Dr. Martyn D. Winn of the Scientific
Computing Department, STFC Daresbury Laboratory, Warrington, UK, for
providing coordinates for a head-to-head EGFR tetramer model and
allowing our inclusion of the coordinates as Additional file 1: Data S1.
Author details
1Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman
Ave, Philadelphia, PA 19111, USA. 2Translational Facility, Fox Chase Cancer
Center, 333 Cottman Ave, Philadelphia, PA 19111, USA. 3Biostatistics and
Bioinformatics Facility, Fox Chase Cancer Center, 333 Cottman Ave,
Philadelphia, PA 19111, USA. 4Kazan Federal University, Kazan, Russia.
Received: 20 December 2014 Accepted: 5 May 2015References
1. Sibilia M, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt FM, et al. The
EGF receptor provides an essential survival signal for SOS-dependent skin
tumor development. Cell. 2000;102(2):211–20.
2. Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid
M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic
ductal adenocarcinoma. Cancer Cell. 2012;22(3):318–30.
3. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS,
et al. Structural alterations of the epidermal growth factor receptor gene in
human gliomas. Proc Natl Acad Sci U S A. 1992;89(7):2965–9.
4. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov
I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin
Ther Targets. 2009;13(3):339–62.
5. Gan HK, Burgess AW, Clayton AH, Scott AM. Targeting of a conformationally
exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.
Cancer Res. 2012;72(12):2924–30.
6. Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, et al.
Phase I/II trial of cetuximab and erlotinib in patients with lung
adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res.
2011;17(8):2521–7.
7. Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, et al. Dual
targeting of the epidermal growth factor receptor using the combination of
cetuximab and erlotinib: preclinical evaluation and results of the phase II
DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin
Oncol. 2012;30(13):1505–12.
8. Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family: not so
prototypical receptor tyrosine kinases. Cold Spring Harbor perspectives in
biology. 2014;6(4):a020768.
9. Needham SR, Zanetti-Domingues LC, Hirsch M, Rolfe DJ, Tynan CJ, Roberts
SK, et al. Structure-function relationships and supramolecular organization
of the EGFR (epidermal growth factor receptor) on the cell surface. Biochem
Soc Trans. 2014;42(1):114–9.
10. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, et al.
An open-and-shut case? Recent insights into the activation of EGF/ErbB
receptors. Mol Cell. 2003;12(3):541–52.
11. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA.
EGF activates its receptor by removing interactions that autoinhibit
ectodomain dimerization. Mol Cell. 2003;11(2):507–17.
12. Alvarado D, Klein DE, Lemmon MA. Structural basis for negative
cooperativity in growth factor binding to an EGF receptor. Cell.
2010;142(4):568–79.
13. Wang Q, Villeneuve G, Wang Z. Control of epidermal growth factor receptor
endocytosis by receptor dimerization, rather than receptor kinase activation.
EMBO Rep. 2005;6(10):942–8.
14. Sawano A, Takayama S, Matsuda M, Miyawaki A. Lateral propagation of EGF
signaling after local stimulation is dependent on receptor density. Dev Cell.
2002;3(2):245–57.
15. Ariotti N, Liang H, Xu Y, Zhang Y, Yonekubo Y, Inder K, et al. Epidermal
growth factor receptor activation remodels the plasma membrane lipid
environment to induce nanocluster formation. Mol Cell Biol.
2010;30(15):3795–804.
16. Clayton AH, Tavarnesi ML, Johns TG. Unligated epidermal growth factor
receptor forms higher order oligomers within microclusters on A431 cells
Ramirez et al. BMC Cancer  (2015) 15:436 Page 12 of 12that are sensitive to tyrosine kinase inhibitor binding. Biochemistry.
2007;46(15):4589–97.
17. Clayton AH, Walker F, Orchard SG, Henderson C, Fuchs D, Rothacker J, et al.
Ligand-induced dimer-tetramer transition during the activation of the cell
surface epidermal growth factor receptor-A multidimensional microscopy
analysis. J Biol Chem. 2005;280(34):30392–9.
18. Kozer N, Barua D, Orchard S, Nice EC, Burgess AW, Hlavacek WS, et al.
Exploring higher-order EGFR oligomerisation and phosphorylation–a
combined experimental and theoretical approach. Mol Biosyst.
2013;9(7):1849–63.
19. Mehra R, Serebriiskii IG, Dunbrack Jr RL, Robinson MK, Burtness B, Golemis
EA. Protein-intrinsic and signaling network-based sources of resistance to
EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug
resistance updates : reviews and commentaries in antimicrobial and
anticancer chemotherapy. 2011;14(6):260–79.
20. Kastner J, Loeffler HH, Roberts SK, Martin-Fernandez ML, Winn MD.
Ectodomain orientation, conformational plasticity and oligomerization of
ErbB1 receptors investigated by molecular dynamics. J Struct Biol.
2009;167(2):117–28.
21. Tynan CJ, Roberts SK, Rolfe DJ, Clarke DT, Loeffler HH, Kastner J, et al.
Human epidermal growth factor receptor (EGFR) aligned on the plasma
membrane adopts key features of Drosophila EGFR asymmetry. Mol Cell
Biol. 2011;31(11):2241–52.
22. Murali R, Brennan PJ, Kieber-Emmons T, Greene MI. Structural analysis of
p185c-neu and epidermal growth factor receptor tyrosine kinases:
oligomerization of kinase domains. Proc Natl Acad Sci U S A.
1996;93(13):6252–7.
23. Kozer N, Barua D, Henderson C, Nice EC, Burgess AW, Hlavacek WS, et al.
Recruitment of the adaptor protein Grb2 to EGFR tetramers. Biochemistry.
2014;53(16):2594–604.
24. Chen CH, Chernis GA, Hoang VQ, Landgraf R. Inhibition of heregulin
signaling by an aptamer that preferentially binds to the oligomeric form of
human epidermal growth factor receptor-3. Proc Natl Acad Sci U S A.
2003;100(16):9226–31.
25. Zhang Q, Park E, Kani K, Landgraf R. Functional isolation of activated and
unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds
in ligand-dependent signaling. Proc Natl Acad Sci U S A.
2012;109(33):13237–42.
26. Landgraf R, Eisenberg D. Heregulin reverses the oligomerization of HER3.
Biochemistry. 2000;39(29):8503–11.
27. Park E, Baron R, Landgraf R. Higher-order association states of cellular ERBB3
probed with photo-cross-linkable aptamers. Biochemistry.
2008;47(46):11992–2005.
28. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide:
a new approach for rapid, accurate docking and scoring. 1. Method and
assessment of docking accuracy. J Med Chem. 2004;47(7):1739–49.
29. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA,
et al. Extra precision glide: docking and scoring incorporating a model of
hydrophobic enclosure for protein-ligand complexes. J Med Chem.
2006;49(21):6177–96.
30. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al.
Glide: a new approach for rapid, accurate docking and scoring. 2.
Enrichment factors in database screening. J Med Chem. 2004;47(7):1750–9.
31. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision
making by early and delayed loops. Nat Rev Mol Cell Biol.
2011;12(2):104–17.
32. Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, et al.
Targeting C4-demethylating genes in the cholesterol pathway sensitizes
cancer cells to EGF receptor inhibitors via increased EGF receptor degradation.
Cancer discovery. 2013;3(1):96–111.
33. Zheng Y, Zhang C, Croucher DR, Soliman MA, St-Denis N, Pasculescu A,
et al. Temporal regulation of EGF signalling networks by the scaffold protein
Shc1. Nature. 2013;499(7457):166–71.
34. Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X,
et al. VAV3 mediates resistance to breast cancer endocrine therapy. Breast
cancer research: BCR. 2014;16(3):R53.
35. Dayekh K, Johnson-Obaseki S, Corsten M, Villeneuve PJ, Sekhon HS,
Weberpals JI, et al. Monensin inhibits epidermal growth factor receptor
trafficking and activation: synergistic cytotoxicity in combination with
EGFR inhibitors. Mol Cancer Ther. 2014;13(11):2559–71.36. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI,
et al. The biologic effects of C225, a chimeric monoclonal antibody to the
EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor
Immunol. 1996;19(6):419–27.
37. Prewett M, Rockwell P, Rose C, Goldstein N. Anti-tumor and cell cycle
responses in KB cells treated with a chimeric anti-EGFR monoclonal
antibody in combination with cisplatin. Int J Oncol. 1996;9(2):217–24.
38. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan
BW, et al. Irreversible inhibitors of the EGF receptor may circumvent
acquired resistance to gefitinib. Proc Natl Acad Sci U S A.
2005;102(21):7665–70.
39. Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y,
et al. Synthetic lethal screen of an EGFR-centered network to improve
targeted therapies. Sci Signal. 2010;3(140):ra67.
40. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural
basis for inhibition of the epidermal growth factor receptor by cetuximab.
Cancer Cell. 2005;7(4):301–11.
41. Jaffe EK. Impact of quaternary structure dynamics on allosteric drug
discovery. Curr Top Med Chem. 2013;13(1):55–63.
42. Gabizon R, Friedler A. Allosteric modulation of protein oligomerization: an
emerging approach to drug design. Frontiers in chemistry. 2014;2:9.
43. Bornholdt ZA, Noda T, Abelson DM, Halfmann P, Wood MR, Kawaoka Y,
et al. Structural rearrangement of ebola virus VP40 begets multiple
functions in the virus life cycle. Cell. 2013;154(4):763–74.
44. Lawrence SH, Ramirez UD, Tang L, Fazliyez F, Kundrat L, Markham GD, et al.
Shape shifting leads to small-molecule allosteric drug discovery. Chem Biol.
2008;15(6):586–96.
45. Jaffe EK, Lawrence SH. Allostery and the dynamic oligomerization of
porphobilinogen synthase. Arch Biochemi Biophys. 2012;519(2):144–53.
46. Lawrence SH, Ramirez UD, Selwood T, Stith L, Jaffe EK. Allosteric inhibition
of human porphobilinogen synthase. J Biol Chem. 2009;284(51):35807–17.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
